Rubius Therapeutics Inc. [NASDAQ: RUBY] gained 5.90% or 0.05 points to close at $0.98 with a heavy trading volume of 29310339 shares. The company report on August 9, 2022 that Rubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
New Preclinical Data Presented at the FOCIS 2022 Annual Meeting Demonstrating Prevention of Type 1 Diabetes in a Stringent Preclinical Model.
Initial Clinical Results Expected in 2H’22 from Phase 1 Arm of RTX-240 + Pembrolizumab in Advanced Solid Tumors and Expansion Cohorts in Non-Small Cell Lung Cancer (NSCLC) and Renal Cell Carcinoma (RCC).
It opened the trading session at $1.15, the shares rose to $1.24 and dropped to $0.953, the range by which the price of stock traded the whole day. The daily chart for RUBY points out that the company has recorded -78.27% loss over the past six months. However, it is still -50.77% lower than its most recent low trading price.
If we look at the average trading volume of 714.05K shares, RUBY reached to a volume of 29310339 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Rubius Therapeutics Inc. [RUBY]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RUBY shares is $6.80 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RUBY stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Rubius Therapeutics Inc. shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on October 19, 2021. While these analysts kept the previous recommendation, SVB Leerink raised their target price from $19 to $4. The new note on the price target was released on March 13, 2020, representing the official price target for Rubius Therapeutics Inc. stock. Previously, the target price had yet another raise to $4, while Morgan Stanley analysts kept a Equal-Weight rating on RUBY stock.
The Average True Range (ATR) for Rubius Therapeutics Inc. is set at 0.09 The Price to Book ratio for the last quarter was 0.92, with the Price to Cash per share for the same quarter was set at 1.92.
Trading performance analysis for RUBY stock
Rubius Therapeutics Inc. [RUBY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 43.67. With this latest performance, RUBY shares gained by 27.27% in over the last four-week period, additionally sinking by -78.27% over the last 6 months – not to mention a drop of -95.61% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RUBY stock in for the last two-week period is set at 69.00, with the RSI for the last a single of trading hit 77.70, and the three-weeks RSI is set at 60.14 for Rubius Therapeutics Inc. [RUBY]. The present Moving Average for the last 50 days of trading for this stock 0.7919, while it was recorded at 0.8033 for the last single week of trading, and 4.4734 for the last 200 days.
Rubius Therapeutics Inc. [RUBY]: A deeper dive into fundamental analysis
Return on Equity for this stock declined to -122.71, with Return on Assets sitting at -65.98.
Rubius Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.60 and a Current Ratio set at 4.60.
An analysis of insider ownership at Rubius Therapeutics Inc. [RUBY]
There are presently around $77 million, or 87.30% of RUBY stock, in the hands of institutional investors. The top three institutional holders of RUBY stocks are: FLAGSHIP PIONEERING INC. with ownership of 38,506,526, which is approximately 0% of the company’s market cap and around 5.20% of the total institutional ownership; FMR LLC, holding 13,528,925 shares of the stock with an approximate value of $13.26 million in RUBY stocks shares; and BAILLIE GIFFORD & CO, currently with $4.81 million in RUBY stock with ownership of nearly -0.028% of the company’s market capitalization.
Positions in Rubius Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 39 institutional holders increased their position in Rubius Therapeutics Inc. [NASDAQ:RUBY] by around 4,186,148 shares. Additionally, 85 investors decreased positions by around 15,094,968 shares, while 8 investors held positions by with 59,354,896 shares. The mentioned changes placed institutional holdings at 78,636,012 shares, according to the latest SEC report filing. RUBY stock had 19 new institutional investments in for a total of 1,537,500 shares, while 57 institutional investors sold positions of 6,201,870 shares during the same period.